The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.
November 22nd 2024
Francisco J. Esteva, MD, PhD, highlights various pivotal studies for the treatment of HER2-positive early-stage breast cancer.
Blood Test May Predict Palbociclib Response Earlier in Breast Cancer
A blood test that detects early changes in circulating tumor DNA may provide an earlier indication of whether patients with hormone receptor–positive, HER2-negative breast cancer are responding to palbociclib (Ibrance).
European Panel Recommends Against Neratinib for HER2-Positive Breast Cancer
European regulators have recommended against approving a marketing authorization application for the use of neratinib (Nerlynx) as extended adjuvant treatment for women with early stage HER2-positive breast cancer.
Dr. Isaacs Discusses the Future of Treatment for HER2+ Breast Cancer
February 14th 2018Claudine Isaacs, MD, professor, medical director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses the future of treatment for patients with HER2-positive breast cancer.
Neoadjuvant Palbociclib/Pertuzumab Regimen Active in ER/HER2-Positive Breast Cancer
The neoadjuvant combination of palbociclib (Ibrance), pertuzumab (Perjeta), fulvestrant (Faslodex), and trastuzumab (Herceptin), cut expression of Ki67 and induced an overall clinical response of 29% in women with ER-positive/HER2-positive breast cancer.